MLICM
CERE

Metropolitan Life Insurance Company (MetLife)’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,833
Closed -$162K – 2260
2024
Q1 		$162K Sell
3,833
-156
-4% -$6.55K 0.01% 799
2023
Q4 		$169K Buy
3,989
+367
+10% +$10.5K 0.01% 816
2023
Q3 		$79.1K Buy
3,622
+224
+7% +$5.61K ﹤0.01% 1144
2023
Q2 		$108K Buy
3,398
+103
+3% +$3.16K 0.01% 978
2023
Q1 		$80.4K Sell
3,295
-292
-8% -$8.57K ﹤0.01% 1118
2022
Q4 		$113K Buy
3,587
+240
+7% +$6.77K 0.01% 984
2022
Q3 		$94.6K Hold
3,347
– – ﹤0.01% 1052
2022
Q2 		$88.5K Buy
3,347
+544
+19% +$15.4K ﹤0.01% 1128
2022
Q1 		$98.1K Sell
2,803
-9,285
-77% -$271K ﹤0.01% 1204
2021
Q4 		$392K Buy
12,088
+355
+3% +$12.5K 0.01% 1585
2021
Q3 		$346K Sell
11,733
-420
-3% -$11.8K 0.01% 1674
2021
Q2 		$311K Buy
+12,153
New +$174K ﹤0.01% 1835

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CERE Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 3,833 shares — an estimated $162K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CERE in Q2 2021 and held it in 12 quarters. The position peaked at $392K in Q4 2021. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,833 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $162K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $392K in Q4 2021.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.